Dr. Lucie Germain, Ph.D., is a full professor at the Department of Surgery and Vice Dean of Research and Graduate Studies at Laval University. Within the CHU de Québec-Laval University Research Center, she was Director of the Regenerative Medicine Division until 2014. Her work, dedicated to postnatal stem cells and human tissue reconstruction, led to three clinical trials involving engineered tissues produced in vitro applied to the treatment of venous ulcers, severely burned patients and limbal stem cell deficiency of the cornea. Dr. Germain has published more than 155 peer-reviewed articles, 67 book chapters and reviews and given more than 135 invited seminars and conferences. Her sustainable contribution as health research was recognized by the Foundation scheme of Canadian Institutes of Health Research, which allowed her a financial support for seven years in 2015. The Canada research chair program also recognized Dr. Germain as a leader in the field of stem cells and regenerative medicine by granting her a junior Tier-2 chair in 2001 and a senior Tier 1 chair in 2015. In 2013, she was nominated Member of the Canadian Academy of Health Sciences and was appointed Vice-Dean of Research and Graduate Studies at the Faculty of Medicine of Laval University in 2014.

Improving patients care through the application of her research is at the heart of her motivations. She holds the Research Chair on tissue-engineered organs and translational medicine from the Foundation of Laval University. Her research is dedicated to the reconstruction of human tissues, mainly skin, cornea, blood vessels and heart valves for experimental and clinical applications. The tissue-engineered models developed by Dr. Germain are designed for physiological, pathophysiological or pharmacotoxicological studies. Her research aims to better define molecular signaling pathways involved in stem cell regulation and differentiation. Her work also focuses on improving functionality of reconstructed tissues, for example by adding melanocytes to skin substitutes to improve their pigmentation and UV protection. An important part of her research aims to shorten the time required to produce skin substitutes and to develop a serum-free culture medium for cell and tissue culture. Finally, Dr. Germain actively works on strategies aimed at integrating tissue engineering and gene therapy to find new treatments for genetic skin disorders such as epidermolysis bullosa.

1401, 18e Rue
LOEX / CMDGT
R-109
Québec, Québec
Canada G1J 1Z4
+1 418-525-4444, extension 61696
lucie.germain@crchudequeb... Lucie.germain@fmed.ulaval...

Latest news

245 entries « ‹ 1 of 25 › »

Savard É, Magne B, Simard-Bisson C, Martel C, Larouche D, Gauvin R, Moulin VJ, Germain L

Design of an innovative method for measuring the contractile behaviour of engineered tissues

Journal Article

Tissue Eng Part C Methods, 2024.

Abstract | Links:

Barolet AB, Magne B, Barolet D, Germain L

Differential Nitric Oxide Responses in Primary Cultured Keratinocytes and Fibroblasts to Visible and Near-Infrared Light

Journal Article

Antioxidants (Basel), 13 (10), 2024.

| Links:

Lefrançois P, Doueidari Z, Kleiner O, Manion R, Dutz J, Philip A, Chan AW,

Top 10 research priorities for cutaneous squamous cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative

Journal Article

Br J Dermatol, 190 (3), 2024.

Abstract | Links:

Barbier MA, Ferland K, De Koninck H, Doucet EJ, Dubourget L, Kim M, Cattier B, Morissette A, Bchetnia M, Larouche D, Kim DH, St-Jean G, Germain L

Cancer Spheroids Embedded in Tissue-Engineered Skin Substitutes: A New Method to Study Tumorigenicity In Vivo

Journal Article

Int J Mol Sci, 25 (3), 2024.

Abstract | Links:

Coutant K, Magne B, Ferland K, Fuentes-Rodriguez A, Chancy O, Mitchell A, Germain L, Landreville S

Melanocytes in regenerative medicine applications and disease modeling

Journal Article

J Transl Med, 22 (1), 2024.

Abstract | Links:

Shoimer I, Kleiner O, Manion R, Dutz J, Philip A, Chan AW,

Top 10 research priorities for basal cell carcinoma: results of the Skin Investigation Network of Canada Priority Setting Initiative

Journal Article

Br J Dermatol, 190 (2), 2024.

Abstract | Links:

Bergeron A, Nessim C, Kleiner O, Manion R, Dutz J, Philip A, Chan AW,

Skin Investigation Network of Canada (SkIN Canada) Priority Setting Initiative ranks the top 10 evidence uncertainties for Merkel cell carcinoma

Journal Article

Br J Dermatol, 190 (2), 2024.

Abstract | Links:

Espinoza-Moya ME, Laberge M, Bélanger L, Chang SL, Poder TG, Moulin VJ, Germain L, Beaudoin Cloutier C, Guertin JR

Adaptation of a standardized self-reported cost questionnaire specific for the severe burn injury population (BI-CoPaQ)

Journal Article

Burns, 2024.

Abstract | Links:

Magne B, Ferland K, Savard É, Barbier MA, Morissette A, Larouche D, Beaudoin-Cloutier C, Germain L

The Human Neonatal Skin Fibroblast, an Available Cell Source for Tissue Production and Transplantation, Exhibits Low Risk of Immunogenicity In Vitro

Journal Article

Int J Mol Sci, 25 (13), 2024.

Abstract | Links:

Magne B, Demers A, Savard É, Lemire-Rondeau M, Veillette N, Pruneau V, Guignard R, Morissette A, Larouche D, Auger FA, Germain L

Speeding up the production of clinical-grade skin substitutes using off-the-shelf decellularized self-assembled dermal matrices

Journal Article

Acta Biomater, 167 , 2023.

Abstract | Links:

245 entries « ‹ 1 of 25 › »
Signaler des ajouts ou des modifications

Active projects

  • A human tissue-engineered three-layer cornea (hTEC) supplemented with macrophages as a biomaterial for in vitro studies, from 2024-04-01 to 2029-03-31
  • A multicenter skin research group focusing on novel treatment for epidermolysis, from 2022-12-01 to 2025-02-28
  • Allogeneic dermis to accelerate the production of a tissue-engineered skin substitute to treat Canadian burn patients, from 2023-04-01 to 2025-01-31
  • Chaire de recherche du Canada en Cellules Souches et Génie Tissulaire, from 2022-01-01 to 2028-12-31
  • Chaire de recherche sur les organes reconstruits en laboratoire et leurs applications cliniques (Phase 3), from 2023-12-02 to 2028-12-01
  • Clinical trial of cultured epithelial corneal autografts for the treatment of Canadians with limbal stem cell deficiency, from 2023-04-01 to 2026-01-31
  • Combining tissue-engineered skin with ex vivo gene therapy correction to develop a treatment for epidermolysis bullosa, from 2022-04-01 to 2025-01-31
  • Développement de greffons d’épiderme autologue en combinant thérapie génique et génie tissulaire pour traiter l’épidermolyse bulleuse jonctionnelle, from 2024-04-01 to 2025-03-31
  • GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease, from 2024-04-01 to 2028-03-31
  • Real World Clinical and Economic Burden of Severe Burn Injuries, from 2023-10-01 to 2026-09-30
  • Recherche en vue de développer un traitement pour les patients atteints d'épidermolyse bulleuse dystrophique, from 2021-09-14 to 2025-03-31
  • Régénération de la peau humaine : Une peau reconstruite par génie tissulaire pigmentée produite plus rapidement pour traiter les patients grands brûlés, from 2022-07-01 to 2027-06-30
  • Skin Investigation Network of Canada (SkIN Canada), from 2020-01-01 to 2025-04-30
  • Soutien à la recherche dans le domaine des maladies auto-immunes et de la cicatrisation, from 2016-04-01 to 2027-03-31
  • Tissue engineering to treat Canadian burn patients: the Self-Assembled Skin Substitutes (SASS), from 2022-04-01 to 2026-01-31
  • Tissue-engineered solutions for uro-genital reconstruction, and replacing banned synthetic meshes, from 2021-10-01 to 2026-09-30
  • Urogenital tissue engineering solutions for transgender surgeries, from 2024-03-31 to 2026-03-30

Recently finished projects

  • Cellules souches stromales de cornées humaines pour développer de nouvelles thérapies tissulaires dans le traitement des plaies cornéens, from 2023-03-01 to 2024-03-31
  • Cellules souches stromales de cornées humaines pour développer de nouvelles thérapies tissulaires dans le traitement des plaies cornéens, from 2023-03-01 to 2024-03-31
  • Chaire de recherche sur les organes reconstruits en laboratoire et leurs applications cliniques, from 2013-05-01 to 2023-12-01
  • Cultured epithelial corneal autografts for the treatment of canadians with limbal stem cell deficiency, from 2020-01-01 to 2023-01-31
  • La réponse immunitaire aux peaux reconstruites avec des cellules allogéniques., from 2022-04-01 to 2023-03-31
  • Projets structurants ThéCell 2023-2024_Greffons d’épiderme autologue en combinant thérapie génique et génie tissulaire pour traiter l’épidermolyse bulleuse jonctionnelle, from 2023-04-01 to 2024-03-31
  • Self-Assembly Skin Substitutes (SASS) for the treatment of acute wounds of Canadian burn patients, from 2020-01-01 to 2023-01-31
  • Towards an epidermolysis bullosa clinical trial with tissue-engineered skin after ex vivo gene therapy correction, from 2020-08-01 to 2023-01-31
Data provided by the Université Laval research projects registery